Patents by Inventor Christian NILEWSKI
Christian NILEWSKI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240025919Abstract: Provided herein are aza-tetracyclic oxazepinyl compounds useful in the treatment of cancers.Type: ApplicationFiled: May 19, 2023Publication date: January 25, 2024Inventors: Matthew Leo Landry, Christian Nilewski, Michael Siu, Elisia Villemure, Yong Wang, BinQing Wei, Melissa Ann Ashley, Steven Do, Lewis John Gazzard, Samantha Alyson Green
-
Publication number: 20230295179Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: ApplicationFiled: May 26, 2023Publication date: September 21, 2023Inventors: Justin T. ERNST, Siegfried H. REICH, Paul A. SPRENGELER, Chinh Viet TRAN, Garrick Kenneth PACKARD, Alan X. XIANG, Christian NILEWSKI, Theo MICHELS
-
Publication number: 20230159555Abstract: Described herein are compounds of Formula (I), Formula (I-A), and Formula (I-B), solvates thereof, tautomers thereof, and pharmaceutically acceptable salts of the foregoing, Further described herein are methods of inhibiting NLRP3 using said compounds, and methods of and compositions useful in treating NLRP3-dependent disorders.Type: ApplicationFiled: July 21, 2022Publication date: May 25, 2023Applicant: Genentech, Inc.Inventors: Paul GIBBONS, Kwong Wah LAI, Christian NILEWSKI, Richard M. PASTOR, Steven Thomas STABEN, Craig STIVALA, Bing-Yan ZHU, Huifen CHEN
-
Publication number: 20230108594Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X1, X2, X3, X4, X5, X6, Q, L1, L2, Y, R1, R2, R3, R4, R5, R6, R7, R8 and rings A, B and C are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4e and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: ApplicationFiled: January 28, 2022Publication date: April 6, 2023Inventors: Samuel SPERRY, Alan X. XIANG, Justin T. ERNST, Siegfried H. REICH, Paul A. SPRENGELER, Mike SHAGHAFI, Theo Michels, Christian NILEWSKI, Chinh Viet TRAN, Garrick Kenneth PACKARD, Alan GRUBBS, Kaveri URKALAN, Takasuke MUKAIYAMA
-
Publication number: 20230071483Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: ApplicationFiled: April 14, 2022Publication date: March 9, 2023Inventors: Justin T. ERNST, Siegfried H. Reich, Paul A. Sprengeler, Chinh Viet TRAN, Garrick Kenneth PACKARD, Alan X. XIANG, Christian NILEWSKI, Theo MICHELS
-
Patent number: 11440917Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: GrantFiled: February 28, 2020Date of Patent: September 13, 2022Assignee: EFFECTOR THERAPEUTICS, INC.Inventors: Justin T. Ernst, Siegfried H. Reich, Paul A. Sprengeler, Chinh Viet Tran, Garrick Kenneth Packard, Alan X. Xiang, Christian Nilewski, Theo Michels
-
Patent number: 11286268Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X1, X2, X3, X4, X5, X6, Q, L1, L2, Y, R1, R2, R3, R4, R5, R6, R7, R8 and rings A, B and C are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4e and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: GrantFiled: June 30, 2020Date of Patent: March 29, 2022Assignee: eFFECTOR Therapeutics, Inc.Inventors: Samuel Sperry, Alan X. Xiang, Justin T. Ernst, Siegfried H. Reich, Paul A. Sprengeler, Mike Shaghafi, Theo Michels, Christian Nilewski, Chinh Viet Tran, Garrick Kenneth Packard, Alan Grubbs, Kaveri Urkalan, Takasuke Mukaiyama
-
Publication number: 20200339590Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: ApplicationFiled: February 28, 2020Publication date: October 29, 2020Applicant: eFector Therapautics, Inc.Inventors: Justin T. Ernst, Siegfried H. Reich, Paul A. Sprengeler, Chinh Viet Tran, Garrick Kenneth Packard, Alan X. Xiang, Christian Nilewski, Theo Michels
-
Patent number: 10577378Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: GrantFiled: March 12, 2018Date of Patent: March 3, 2020Assignee: eFFECTOR Therapeutics, Inc.Inventors: Justin T. Ernst, Siegfried H. Reich, Paul A. Sprengeler, Chinh Viet Tran, Garrick Kenneth Packard, Alan X. Xiang, Christian Nilewski, Theo Michels
-
Publication number: 20180298017Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: ApplicationFiled: March 12, 2018Publication date: October 18, 2018Applicant: eFFECTOR Therapeutics, Inc.Inventors: Justin T. ERNST, Siegfried H. REICH, Paul A. SPRENGELER, Chinh Viet TRAN, Garrick Kenneth PACKARD, Alan X. XIANG, Christian NILEWSKI, Theo MICHELS
-
Patent number: 10065924Abstract: In one aspect, the present invention provides novel derivatives of viridicatumtoxin of the formula wherein the variables are as defined herein. The application also provides compositions, methods of treatment, and methods of synthesis thereof.Type: GrantFiled: July 22, 2015Date of Patent: September 4, 2018Assignee: WILLIAM MARSH RICE UNIVERSITYInventors: Kyriacos C Nicolaou, Christopher R. H. Hale, Christian Nilewski, Heraklidia Ioannidou, Abdellatif El Marrouni
-
Patent number: 9957277Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: GrantFiled: November 22, 2016Date of Patent: May 1, 2018Assignee: eFFECTOR Therapeutics, Inc.Inventors: Justin T. Ernst, Siegfried H. Reich, Paul A. Sprengeler, Chinh Viet Tran, Garrick Kenneth Packard, Alan X. Xiang, Christian Nilewski, Theo Michels
-
Publication number: 20170210699Abstract: In one aspect, the present invention provides novel derivatives of viridicatumtoxin of the formula wherein the variables are as defined herein. The application also provides compositions, methods of treatment, and methods of synthesis thereof.Type: ApplicationFiled: July 22, 2015Publication date: July 27, 2017Applicant: WILLIAM MARSH RICE UNIVERSITYInventors: Kyriacos C NICOLAOU, Christopher R.H. HALE, Christian NILEWSKI, Heraklidia IOANNIDOU, Abdellatif EL MARROUNI
-
Publication number: 20170145026Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.Type: ApplicationFiled: November 22, 2016Publication date: May 25, 2017Inventors: Justin T. ERNST, Siegfried H. REICH, Paul A. SPRENGELER, Chinh Viet TRAN, Garrick Kenneth PACKARD, Alan X. XIANG, Christian NILEWSKI, Theo MICHELS